Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Perets, Ruth
NCT06478862: Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy	Recruiting	2	20	RoW	Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug	Lipomedix Pharmaceuticals Inc.	Cancer of Ovary, Pancreatic Ductal Adenocarcinoma	06/26	01/27
NCT05581719 / 2022-003063-21: A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy	Terminated	1/2	14	Europe, RoW	Allocetra-OTS, Nivolumab, Tislelizumab	Enlivex Therapeutics RDO Ltd., Enlivex Therapeutics RDO, Ltd.	Solid Tumor, Peritoneal Metastases, Peritoneal Cancer	04/24	04/24
AM003-FIH-001, NCT06258330: Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors	Active, not recruiting	1	12	RoW	AM003	Aummune Ltd.	Solid Tumor	07/24	01/25
NCT04990739: Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors	Recruiting	1	30	US, RoW	MTB-9655	MetaboMed Inc	Advanced Solid Tumor	01/24	01/24
BMC128-001, NCT05354102: A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128	Active, not recruiting	1	11	RoW	BMC128, LBP (Live Bacteria Product), Nivolumab, Opdivo	Biomica Ltd.	Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma	05/24	11/25
BND-35-001, NCT06274437: A Study of BND-35 in Participants With Advanced Solid Tumors	Recruiting	1	280	RoW	BND-35, Monoclonal antibody, Nivolumab, Opdivo, Cetuximab, Erbitux	Biond Biologics	Cancer	09/27	11/27